Dashboard
1
Poor Management Efficiency with a low ROCE of 5.04%
- The company has been able to generate a Return on Capital Employed (avg) of 5.04% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of 0.52% and Operating profit at 11.03% over the last 5 years
3
Flat results in Jun 25
4
With ROE of 6.35%, it has a expensive valuation with a 0.87 Price to Book Value
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 839 Million (Small Cap)
14.00
NA
2.06%
-0.46
7.00%
0.83
Revenue and Profits:
Net Sales:
236 Million
(Quarterly Results - Sep 2025)
Net Profit:
24 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.64%
0%
-8.64%
6 Months
2.63%
0%
2.63%
1 Year
75.27%
0%
75.27%
2 Years
47.51%
0%
47.51%
3 Years
60.11%
0%
60.11%
4 Years
-5.55%
0%
-5.55%
5 Years
-21.35%
0%
-21.35%
Guangdong Transtek Medical Electronics Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.52%
EBIT Growth (5y)
11.03%
EBIT to Interest (avg)
14.78
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.46
Sales to Capital Employed (avg)
0.73
Tax Ratio
2.70%
Dividend Payout Ratio
98.35%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.04%
ROE (avg)
3.73%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
0.87
EV to EBIT
8.26
EV to EBITDA
5.75
EV to Capital Employed
0.77
EV to Sales
0.43
PEG Ratio
0.75
Dividend Yield
1.98%
ROCE (Latest)
9.26%
ROE (Latest)
6.35%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
235.80
248.10
-4.96%
Operating Profit (PBDIT) excl Other Income
24.70
25.90
-4.63%
Interest
1.40
0.80
75.00%
Exceptional Items
-0.30
-1.10
72.73%
Consolidate Net Profit
23.50
18.50
27.03%
Operating Profit Margin (Excl OI)
104.60%
72.50%
3.21%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is -4.96% vs -8.55% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 27.03% vs -18.86% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
979.00
879.50
11.31%
Operating Profit (PBDIT) excl Other Income
81.40
47.10
72.82%
Interest
6.90
4.80
43.75%
Exceptional Items
-12.50
-0.10
-12,400.00%
Consolidate Net Profit
58.20
31.20
86.54%
Operating Profit Margin (Excl OI)
52.40%
16.20%
3.62%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 11.31% vs -16.84% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 86.54% vs 181.68% in Dec 2023
About Guangdong Transtek Medical Electronics Co., Ltd. 
Guangdong Transtek Medical Electronics Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






